Skip to main content

Closed

BBIO: BridgeBio Pharma, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+2285.3% / yr

Operating margin-98.4%

ROIC-57.9%

Financially safe

Stretched

Debt / equity-1.49×

Interest coverage-5.0×

Current ratio1.44×

BridgeBio Pharma, Inc.

BBIONASDAQ Global Select·USD·Closed

BridgeBio Pharma, Inc.

BBIONASDAQ·USD·Closed

$80.09

−2.50%

$80.09

−$2.05 (2.50%)

52W Range

74thpctl

Volume

0.61×avg

Mkt Cap

15.69BUSD

P/E

-17.7TTM

Div Yield

–ann

52W Range

74thpctl

Volume

0.61×avg

Market Cap

15.69BUSD

P/E Ratio

-17.7TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings